COST-EFFECTIVENESS MODEL OF LEBRIKIZUMAB COMPARED TO DUPILUMAB IN THE TREATMENT OF AUSTRIAN PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS

被引：0
|
作者：
Schwarz, B. [1 ]
Sole-Feu, L. [2 ]
Akmaz, B. [3 ]
机构：
[1] Med Univ Vienna, Vienna, Austria
[2] Almirall SA, Barcelona, Catalonia, Spain
[3] Pricing & Med Affairs Almirall SA, Reinbek, SH, Germany
来源：
VALUE IN HEALTH | 2024年 / 27卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE705
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Dupilumab (Dupixent) for Moderate to Severe Atopic Dermatitis
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2017, 59 (1519): : 64 - 66
  • [22] Lebrikizumab is an effective treatment for moderate-to-severe atopic dermatitis in patients ≥60 years of age
    Armstrong, April
    Zirwas, Matthew
    Napolitano, Maddalena
    Torres, Tiago
    Staumont-Salle, Delphine
    Atwater, Amber Reck
    Dossenbach, Martin
    Agell, Helena
    Chen, Sherry
    Qiao, Meihua
    Pierce, Evangeline
    Piruzeli, Maria Lucia Buziqui
    Mostaghimi, Arash
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 191
  • [23] DUPILUMAB TREATMENT RAPIDLY IMPROVES ITCH IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS
    Silverberg, J.
    Chao, J.
    Eckert, L.
    Chen, Z.
    Ardeleanu, M.
    Shumel, B.
    Plaum, S.
    Graham, N.
    Pirozzi, G.
    Gadkari, A.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2017, 119 (05) : S95 - S95
  • [24] Dupilumab Treatment Rapidly Improves Itch in Patients With Moderate-to-Severe Atopic Dermatitis
    Silverberg, Jonathan I.
    Chao, Jingdong
    Eckert, Laurent
    Chen, Zhen
    Ardeleanu, Marius
    Shumel, Brad
    Plaum, Stefan
    Graham, Neil M. H.
    Pirozzi, Gianluca
    Gadkari, Abhijit
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2018, 16 : 29 - 29
  • [25] Improved and cleared facial and hand dermatitis with lebrikizumab in patients with moderate-to-severe atopic dermatitis
    Murase, Jenny E.
    Chovatiya, Raj
    Strowd, Lindsay
    Thyssen, Jacob P.
    Bangert, Christine
    Atwater, Amber Reck
    Gallo, Gaia
    Bardolet, Laia
    Yang, Fan
    Zhong, Jinglin
    Staumont-Salle, Delphine
    BRITISH JOURNAL OF DERMATOLOGY, 2023, 188
  • [26] Short- and long-term cost-effectiveness of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis in China
    Shi, Yin
    Zhou, Yanwu
    Li, Shuishi
    Guan, Haijing
    Liu, Shao
    JOURNAL OF MEDICAL ECONOMICS, 2024, 27 (01) : 1180 - 1189
  • [27] COST-EFFECTIVENESS OF EMOLLIENTS IN PATIENTS WITH ATOPIC DERMATITIS
    Cabout, E.
    Trouiller, J. B.
    Launois, R.
    Taieb, C.
    Seite, S.
    VALUE IN HEALTH, 2019, 22 : S901 - S901
  • [28] Psoriasiform dermatitis during dupilumab treatment for moderate-to-severe atopic dermatitis in children
    Parker, Jennifer J.
    Sugarman, Jeffrey L.
    Silverberg, Nanette B.
    Gonzalez, Mercedes Elena
    Ramien, Michele L.
    Teng, Joyce M. C.
    Paller, Amy S.
    PEDIATRIC DERMATOLOGY, 2021, 38 (06) : 1500 - 1505
  • [29] Dupilumab: A Review in Moderate-to-Severe Atopic Dermatitis
    James E. Frampton
    Hannah A. Blair
    American Journal of Clinical Dermatology, 2018, 19 : 617 - 624
  • [30] Dupilumab: A Review in Moderate-to-Severe Atopic Dermatitis
    Frampton, James E.
    Blair, Hannah A.
    AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2018, 19 (04) : 617 - 624
12345